Eton Pharmaceuticals, Inc.
NASDAQ:ETONBiotechnology
-$0.46 today
- Market cap
- $1.79B
- Beta
- 0.89
- P/E (TTM)
- -597.6
- EPS (TTM)
- -$0.05
Volume 0.48M
Average 0.43M
ETON Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Eton Pharmaceuticals, Inc.NASDAQ: ETON
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue grows, but more slowly than its trailing trend
Q1 FY2026 cost of revenue of $9.53M rose 28.4% year over year, behind the +96.0% change in trailing-twelve-month cost of revenue. Sequentially, it rose 16.5% from the prior quarter. Over 3 fiscal years it compounded at +75.1% a year.
Context
- Cost of revenue amounted to 46.5% of revenue in FY2025, up 6.6 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +28.4% toward the trailing-twelve-month pace of +96.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 37.21M USD
- Year-over-year change
- +138.5%
- 4-year CAGR
- +94.1%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 37.21M | +138.5% |
| FY2024 | 2024-12-31 | 15.6M | +47.4% |
| FY2023 | 2023-12-31 | 10.58M | +52.6% |
| FY2022 | 2022-12-31 | 6.93M | +164.3% |
| FY2021 | 2021-12-31 | 2.62M | — |
Cost of Revenue vs competitors
How ETON compares with its peers on the latest reported figures
- ETON's LTM Mar 2026 cost of revenue of $39.32M is the 3rd highest of the 10 companies compared; the peer median is $17.04M.
- Its year-over-year change of +96.0% is the 3rd highest of 8, against a peer median of +32.9%.
- Cost of revenue amounts to 45.2% of revenue for ETON, versus a peer median of 7.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $109.99M | +25.2% | +56.7% | 16.4% | |
| LTM Mar 2026 | $46.97M | +32.9% | +37.5% | 12.7% | |
| LTM Mar 2026 | $39.32M | +96.0% | +75.1% | 45.2% | |
| LTM Sep 2026 | $31.49M | +204.6% | +32.7% | 4.8% | |
| LTM Mar 2026 | $17.72M | +106.3% | +320.3% | 14.5% | |
| LTM Sep 2026 | $17.04M | +44.2% | +4.3% | 1.8% | |
| LTM Mar 2026 | $3.96M | +31.7% | +252.4% | 7.8% | |
| LTM Mar 2026 | $646K | -97.5% | -82.7% | 0.9% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding ETON) | $17.04M | +32.9% | +37.5% | 7.8% | |
Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 21.83M | 21.25M | 31.64M | 39.01M | 79.95M |
| Cost of Revenue | 2.62M | 6.93M | 10.58M | 15.6M | 37.21M |
| Gross Profit | 19.21M | 14.32M | 21.06M | 23.41M | 42.74M |
| Gross Margin | 88.0% | 67.4% | 66.6% | 60.0% | 53.5% |
| Research & Development | 6.24M | 4M | 3.32M | 3.26M | 7.77M |
| Selling, General & Admin | 14.47M | 18.58M | 18.93M | 22.75M | 35.82M |
| Operating Expenses | 20.7M | 22.58M | 22.25M | 26.01M | 42.67M |
| Depreciation & Amortization | 462K | 1.77M | 901K | 1.15M | 4.04M |
| EBITDA | (1.49M) | (7.25M) | 212K | (657K) | 4.27M |
| EBITDA Margin | -6.8% | -34.1% | 0.7% | -1.7% | 5.3% |
| Operating Income | (1.5M) | (8.26M) | (1.19M) | (2.6M) | 72K |
| Operating Margin | -6.8% | -38.9% | -3.8% | -6.7% | 0.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.04M | 955K | 1.06M | 2.01M | 4.78M |
| Other Income / Expenses | (460K) | (761K) | 503K | (1.21M) | (4.63M) |
| Income Before Tax | (1.96M) | (9.02M) | (689K) | (3.81M) | (4.56M) |
| Pre-Tax Margin | -9.0% | -42.4% | -2.2% | -9.8% | -5.7% |
| Income Tax Expense | 0 | 0 | 247K | 15K | 43K |
| Net Income | (1.96M) | (9.02M) | (936K) | (3.82M) | (4.6M) |
| Net Margin | -9.0% | -42.4% | -3.0% | -9.8% | -5.8% |
| EPS (Basic) | (0.08) | (0.36) | (0.04) | (0.15) | (0.17) |
| EPS (Diluted) | (0.08) | (0.36) | (0.04) | (0.15) | (0.17) |
| Weighted Avg Shares | 25.21M | 25.15M | 25.65M | 25.9M | 26.91M |
| Weighted Avg Shares (Diluted) | 25.21M | 25.15M | 25.65M | 25.9M | 26.91M |
Eton Pharmaceuticals, Inc.
NASDAQ:ETON
Intrinsic Alpha fair value
Locked
Current Price
$61.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.